Propylthiouracil

Phase 3Small molecule

AAultman Health Foundation

Propylthiouracil is one of 64 small molecule programs targeting Stroke. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

StrokeActive, not recruiting

AtherosclerosisActive, not recruiting

ThyrotoxicosisActive, not recruiting

StrokePhase 2

Active, not recruiting

AtherosclerosisPhase 3

Active, not recruiting

ThyrotoxicosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

461 competitors in Stroke

#DrugCompanyPhaseTrials

Propylthiouracil

AAultman Health Foundation

Phase 3

1 2

Activase

Roche

Preclinical

19 3

Zometa

Pfizer

Preclinical

1 4

Folvite

Eli Lilly

Preclinical

1 5

Savella

AbbVie

Preclinical

1 6

Repatha

Amgen

Preclinical

—7

Botox

RRevance Therapeutics, Inc.

Preclinical

2 8

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

Zantac 150

CChattem

Preclinical

1 10

Alka-Seltzer

AAbbott

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Stroke1 trial

Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE

Unknown status·MMaastricht University·Phase 2·NCT05762146·28 enrolled

Thyrotoxicosis1 trial

Antithyroid Drug Treatment of Thyrotoxicosis in Young People

Completed·NNewcastle-upon-Tyne Hospitals NHS Trust·Phase 3·NCT01436994·81 enrolled

Thyroid1 trial

The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy

Unknown status·—·Phase 4·NCT01056419·40 enrolled

Atherosclerosis1 trial

Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis

Completed·IIndonesia University·Phase 3·NCT05118542·36 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

PROPYLTHIOURACIL

NDA NDA006213

Jan 1, 1982

PROPYLTHIOURACIL

NDA NDA006188

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Propylthiouracil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Propylthiouracil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Propylthiouracil. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA006213). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Aultman Health Foundation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAultman Health Foundation

Propylthiouracil

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Stroke1 trial

Thyrotoxicosis1 trial

Thyroid1 trial

Atherosclerosis1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News